Biosyent (RX) Q4 2025 earnings summary

Executive summary

• Achieved double-digit revenue and profit growth in Q4 and FY 2025, driven by Canadian pharma, international Tibelia, and legacy businesses.

• Completed the acquisition of Oral Science Inc. in March 2026, expanding into oral health and diversifying revenue streams.

• Maintained a consistent record of profitability, marking the 62nd consecutive profitable quarter.

• Paid increased quarterly dividends and continued share buybacks, reflecting strong capital returns.

• Continued investment in key brands and new product launches, supporting both Canadian and international growth.

Financial highlights

• Q4 2025 revenue was $9.7M (+10% YoY); FY 2025 revenue was $43.1M (+23% YoY).

• EBITDA was $2.53M in Q4 2025 (+13% YoY) and $12.12M for FY 2025 (+30% YoY).

• Net income after tax for FY 2025 was $9.01M (+24% YoY).

• Fully diluted EPS for FY 2025 was $0.78, up from $0.62 in 2024 and $0.54 in 2023.

• Gross profit for FY 2025 was $32.96M (+18% YoY), with a gross margin of 77%.

Outlook and guidance

• Results for Q1 2026 will include one month of Oral Science; full-year dividend expected to be $0.22 per share.

• Ongoing investment in pharmaceutical and oral health platforms to drive future growth.

• Focus on expanding newly acquired oral health business and maintaining capital-light, cash-flowing operations.

• Further orders for Tibelia Global expected in Q1 2026.

• Continued focus on growth, diversification, and capital allocation for acquisitions and product launches.